{
  "id": 20174509,
  "title": "Clover Health’s Conrad Wai, CEO of Counterpart Health, sells $1.42M in stock",
  "url": "https://urgent.news/2026/11/15/clover-healths-conrad-wai-ceo-of-counterpart-health-sells-1-42m-in",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-15T12:30:58.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/clover-healths-conrad-wai-ceo-of-counterpart-health-sells-142m-in-stock-93CH-5027898"
  },
  "original_language": "en",
  "account": "Conrad Wai, CEO of Counterpart Health, sold 300,000 shares of Clover Health Investments (CLOV) stock on September 15, 2026. The transaction was valued at $1.42 million and took place in multiple trades, with share prices fluctuating between $4.60 and $5.06. Mr. Wai adopted a Rule 10b5-1 trading plan for this sale on June 8, 2026. Following the stock sale, Wai still holds 1,065,699 shares of Class A Common Stock, and indirectly owns 1,170,056 shares through a family trust he co-trusts. Clover Health reported strong third-quarter results, surpassing analysts' expectations, with adjusted earnings of $0.01 per share and revenue of $759.3 million. Needham reiterated its Buy rating on the stock, with a price target of $6.00, anticipating the 2025 and 2026 cohorts to greatly contribute to the company's long-term earnings potential.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}